Carna Biosciences: Mass holding report (stock certificates subject to special cases, etc.)
Carna Biosciences: Supplementary explanatory materials on the issuance of new shares through third-party allotment
Carna Biosciences: Notice Concerning Issuance of New Shares through Third-Party Allocation
Carna Biosciences: Interim report
Carna Biosciences: Notice of decision to start BTK inhibitor AS-1763 phase 1b test dose expansion part
Carna Biosciences: Notice of patent assessment in Europe relating to a joint patent application with Gilead Sciences
Carna Biosciences: Confirmatory letter.
Carna Biosciences: Interim report - 22nd term (January 1, 2024 - December 31, 2024)
Carna Biosciences: Financial results presentation materials for the second quarter of the December 2024 period.
Carna Biosciences: 2nd quarter (interim period) financial statements as of December 2024 (Japanese standard) (consolidated)
Carna Biosciences: Report of transfer of new shares for third-party allotment.
Carna Biosciences: Announcements of individual stocks regarding patent assessment in China for BTK inhibitor AS-1763 pharmaceutical composition.
Carna Biosciences: Promising initial data from the phase 1b clinical trial of the next-generation BTK inhibitor AS-1763 targeting mature B-cell tumors will be presented at the European Hematology Association (EHA) in 2024.
Carna Biosciences: Stock transfer report agreement relating to third party allotment (new shares)
Carna Biosciences: Notice regarding completion of payments relating to the issuance of new shares through third-party allotment
Carna Biosciences: Notice of presentation at European Society of Hematology (EHA) 2024 on BTK inhibitor AS-1763
Carna Biosciences: Supplementary explanatory materials on the issuance of new shares through third-party allotment
Carna Biosciences: Notice Concerning Issuance of New Shares through Third-Party Allocation
Carna Biosciences: Extraordinary Report
Carna Biosciences: Confirmation letter
No Data
No Data